Alaunos Therapeutics opened lower at $1.57, compared with its previous close of $1.61. In the last trading session, the stock traded between $1.55 and $1.68. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Alaunos Therapeutics is now worth
$ 1.32
Resulting in a loss of
$ 98.68 (98.68%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.03 (+1.86%)
Day High
$1.68
Day Low
$1.55
Day Open
$1.57
Prev Close
$1.61
Volume
53,835
1W Return
-8.64%
1M Return
55.75%
3M Return
-16.33%
6M Return
-37.64%
1Y Return
-42.05%
Fundamentals
Market Cap ($ Mn)
7
PE Ratio
-
PB Ratio
6.13
PEG Ratio
-
ROE
-177.88%
ROCE
-177.88%
EPS (TTM)
$-0.40
Investment Returns
1 Week
-8.64%
1 Month
55.75%
3 Months
-16.33%
6 Months
-37.64%
9 Months
-37.88%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
14Oct
Alaunos Therapeutics shares halt on upside circuit breaker, up 34.32%
Alaunos Therapeutics shares halted on an upside circuit breaker after rising 34.32%. Company completed acquisition of Velaris Therapeutics and raised $350 million. Proceeds fund operations through 2029 for pulmonary hypertension pipeline. Fairmount-led private placement includes major institutional investors.
29 days ago
18Sep
Alaunos Therapeutics announces $1.12m direct offering of shares and warrants
Alaunos Therapeutics announced a $1.12 million direct offering. Includes 380,469 shares and warrants for up to 386,654 shares. Offer price set at $1.46 per share. Closing expected on or about September 21, 2026. Proceeds to fund general working capital and corporate purposes.
1mo ago
18Sep
Alaunos Therapeutics shares rise 29% after lowering shareholder quorum
Alaunos Therapeutics shares rose 29.28% to $2.07 in after-hours trading. Company adopted Second Amended and Restated By-Laws effective immediately. Stockholder meeting quorum reduced from majority to one-third of voting shares. Stock closed regular session at $1.60, up 25% for the day.
1mo ago
29Jun
Alaunos reports lower liver weight for ALN1003 in preclinical study
Alaunos Therapeutics reported that ALN1003 demonstrated lower liver weight after adjusting for body fat in a 48-day mouse study, consistent with prior data on liver enzymes and insulin resistance. The company holds $0.354 million in cash as of March 31, 2026, and seeks financing for further development.
